Phase 3 Readout
CMPX: Phase 3 Topline: A Phase 2/3 Randomized, Controlled Study of CTX-009 in Combination With Paclitaxel Versus Paclitaxel
December 1, 2026 · ctx-009. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- December 1, 2026
- Company
- Compass Therapeutics, Inc. (CMPX)
- Drug
- ctx-009
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: A Phase 2/3 Randomized, Controlled Study of CTX-009 in Combination With Paclitaxel Versus Paclitaxel
- Drug
- ctx-009
- Indication
- Biliary Tract Cancer; Cholangiocarcinoma; Gall Bladder Cancer